Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.66 |
| ▸ | CPB1 | P15086 | 1/20 | 0.66 |
| ▸ | CPA3 | P15088 | 1/20 | 0.66 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1914987 | 1.00 | CPA1 (0.66) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL2398335 | 1.00 | CPA1 (0.66) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL1912582 | 0.91 | MMEL1 (0.60) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL9755831 | 0.88 | KMT2A (0.54) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL7506768 | 0.88 | KMT2A (0.54) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL10441763 | 0.87 | LTA4H (0.64) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL3965849 | 0.87 | ESR1 (0.58) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL8999162 | 0.87 | KMT2A (0.53) | CPA1CPB1CPA3CPB2KMT2A | |
| SCHEMBL7752235 | 0.87 | KMT2A (0.53) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL22943094 | 0.87 | ANPEP (0.56) | CPA1CPB1CPA3CPB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2003062186-A1 | METAL SALTS OF (3S)-3-METHOXYCARBONYL-4-PHENYLBUTYRIC ACID AND USAGE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | CPA1 953/4885CPB1 939/4885CPA3 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.